Published ahead of print on October 13, 2005, doi:10.1164/rccm.200507-1144OC
American Journal of Respiratory and Critical Care Medicine Vol 173. pp. 180-187, (2006)
© 2006 American Thoracic Society
doi: 10.1164/rccm.200507-1144OC
Rituximab for Refractory Wegener's Granulomatosis
Report of a Prospective, Open-Label Pilot Trial
Karina A. Keogh,
Steven R. Ytterberg,
Fernando C. Fervenza,
Kimberly A. Carlson,
Darrell R. Schroeder and
Ulrich Specks
Divisions of Pulmonary and Critical Care Medicine, Rheumatology, and Nephrology and Hypertension, Department of Medicine, and Division of Biostatistics, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota
Correspondence and requests for reprints should be addressed to Ulrich Specks, M.D., Division of Pulmonary and Critical Care Medicine, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905. E-mail: specks.ulrich{at}mayo.edu
Rationale: Standard therapy for Wegener's granulomatosis is fraught with substantial toxicity and not always effective. B lymphocytes have been implicated in the pathogenesis of Wegener's granulomatosis. Their depletion has been proposed as salvage therapy for refractory disease. Earlier encouraging reports are confounded by concomitant immunosuppressive medications and include only limited available biomarker data.
Objectives: To evaluate the efficacy and safety of rituximab for remission induction in refractory Wegener's granulomatosis.
Methods: A prospective open-label pilot trial was conducted with 10 patients monitored for 1 yr. Included were patients with active severe antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis, ANCA positivity, and resistance to (or intolerance of) cyclophosphamide. The remission induction regimen consisted of oral prednisone (1 mg/kg/d) and four weekly infusions of rituximab (375 mg/m2). Prednisone was tapered and discontinued over 5 mo. Failure to achieve remission, a clinical flare in the absence of B lymphocytes, and inability to complete the glucocorticoid taper were considered treatment failures.
Main Results: Three women and seven men (median age, 57 yr; range, 25–72 yr) were enrolled. All had ANCA reacting with proteinase-3. The median activity score at enrollment was 6 (range, 5–10). All patients tolerated rituximab well, achieved swift B-lymphocyte depletion and complete clinical remission (activity score, 0) by 3 mo, and were tapered off glucocorticoids by 6 mo. Five patients were retreated with rituximab alone for recurring/rising ANCA titers according to protocol. One patient experienced a clinical flare after B lymphocyte reconstitution.
Conclusion: In this cohort, rituximab was a well-tolerated and effective remission induction agent for severe refractory Wegener's granulomatosis.
This article has been cited by other articles:
|
|
|
|
 
P. Berlit
Review: Diagnosis and treatment of cerebral vasculitis
Therapeutic Advances in Neurological Disorders,
January 1, 2010;
3(1):
29 - 42.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. Jayne
Role of Rituximab Therapy in Glomerulonephritis
J. Am. Soc. Nephrol.,
January 1, 2010;
21(1):
14 - 17.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Vincenti, S. D. Cohen, and G. Appel
Novel B Cell Therapeutic Targets in Transplantation and Immune-Mediated Glomerular Diseases
Clin. J. Am. Soc. Nephrol.,
January 1, 2010;
5(1):
142 - 151.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D E Furst, E C Keystone, R Fleischmann, P Mease, F C Breedveld, J S Smolen, J R Kalden, J Braun, B Bresnihan, G R Burmester, et al.
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009
Ann Rheum Dis,
January 1, 2010;
69(Suppl_1):
i2 - i29.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Gomez-Puerta, J. Hernandez-Rodriguez, A. Lopez-Soto, and X. Bosch
Antineutrophil Cytoplasmic Antibody-Associated Vasculitides and Respiratory Disease
Chest,
October 1, 2009;
136(4):
1101 - 1111.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B Terrier, D Saadoun, D Sene, P Ghillani, Z Amoura, G Deray, B Fautrel, J-C Piette, and P Cacoub
Antimyeloperoxidase antibodies are a useful marker of disease activity in antineutrophil cytoplasmic antibody-associated vasculitides
Ann Rheum Dis,
October 1, 2009;
68(10):
1564 - 1571.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M P T Lunn and H J Willison
Diagnosis and treatment in inflammatory neuropathies
Postgrad. Med. J.,
August 1, 2009;
85(1006):
437 - 446.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Eleftheriou, M. Melo, S. D. Marks, K. Tullus, J. Sills, G. Cleary, P. Dolezalova, S. Ozen, C. Pilkington, P. Woo, et al.
Biologic therapy in primary systemic vasculitis of the young
Rheumatology,
August 1, 2009;
48(8):
978 - 986.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Schewior, D. Dragun, B. Rudolph, and E. Schaeffner
Make the grade for Wegener's granulomatosis after kidney transplantation
NDT Plus,
June 1, 2009;
2(3):
199 - 204.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P A Kurz, E B Suhler, D Choi, and J T Rosenbaum
Rituximab for treatment of ocular inflammatory disease: a series of four cases
Br J Ophthalmol,
April 1, 2009;
93(4):
546 - 548.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M P T Lunn and H J Willison
Diagnosis and treatment in inflammatory neuropathies
J. Neurol. Neurosurg. Psychiatry,
March 1, 2009;
80(3):
249 - 258.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C Mukhtyar, L Guillevin, M C Cid, B Dasgupta, K de Groot, W Gross, T Hauser, B Hellmich, D Jayne, C G M Kallenberg, et al.
EULAR recommendations for the management of primary small and medium vessel vasculitis
Ann Rheum Dis,
March 1, 2009;
68(3):
310 - 317.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Specks
Pulmonary Vasculitis and Alveolar Hemorrhage Syndromes
ACCP Pulmonary Med Brd Rev,
January 1, 2009;
25(0):
687 - 704.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Lovric, U. Erdbruegger, P. Kumpers, A. Woywodt, C. Koenecke, H. Wedemeyer, H. Haller, and M. Haubitz
Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 patients
Nephrol. Dial. Transplant.,
January 1, 2009;
24(1):
179 - 185.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Maripuri and F. C. Fervenza
71-Year-Old Man With Shortness of Breath and Rash
Mayo Clin. Proc.,
December 1, 2008;
83(12):
1388 - 1391.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D E Furst, E C Keystone, B Kirkham, R Fleischmann, P Mease, F C Breedveld, J S Smolen, J R Kalden, G R Burmester, J Braun, et al.
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008
Ann Rheum Dis,
December 1, 2008;
67(Suppl_3):
iii2 - iii25.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Ferraro, S. W. Smith, D. Neil, and C. O.S. Savage
Relapsed Wegener's granulomatosis after rituximab therapy--B cells are present in new pathological lesions despite persistent 'depletion' of peripheral blood
Nephrol. Dial. Transplant.,
September 1, 2008;
23(9):
3030 - 3032.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. C. Fervenza, S. Sethi, and U. Specks
Idiopathic Membranous Nephropathy: Diagnosis and Treatment
Clin. J. Am. Soc. Nephrol.,
May 1, 2008;
3(3):
905 - 919.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. D. Salama, H. T. Cook, C. D. Pusey, and R. J. Pepper
A Case of Treated ANCA-Associated Vasculitis with Recurrent Renal Failure
Clin. J. Am. Soc. Nephrol.,
March 1, 2008;
3(2):
637 - 645.
[Full Text]
[PDF]
|
|
|
|
|
|
|
O Flossmann, P Bacon, K de Groot, D Jayne, N Rasmussen, P Seo, K Westman, and R Luqmani
Development of comprehensive disease assessment in systemic vasculitis
Postgrad. Med. J.,
March 1, 2008;
84(989):
143 - 152.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Bosch, A. Guilabert, G. Espinosa, and E. Mirapeix
Treatment of Antineutrophil Cytoplasmic Antibody Associated Vasculitis: A Systematic Review
JAMA,
August 8, 2007;
298(6):
655 - 669.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Jayne
Leflunomide versus methotrexate in Wegener's granulomatosis
Rheumatology,
July 1, 2007;
46(7):
1047 - 1048.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. M Stassen, J. W. Cohen Tervaert, and C. A Stegeman
Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide
Ann Rheum Dis,
June 1, 2007;
66(6):
798 - 802.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. U. Wells and C. M. Hogaboam
Update in Diffuse Parenchymal Lung Disease 2006
Am. J. Respir. Crit. Care Med.,
April 1, 2007;
175(7):
655 - 660.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R Sangle, G. R V Hughes, and D. P D'Cruz
Infliximab in patients with systemic vasculitis that is difficult to treat: poor outcome and significant adverse effects
Ann Rheum Dis,
April 1, 2007;
66(4):
564 - 565.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Tokunaga, K. Saito, D. Kawabata, Y. Imura, T. Fujii, S. Nakayamada, S. Tsujimura, M. Nawata, S. Iwata, T. Azuma, et al.
Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system
Ann Rheum Dis,
April 1, 2007;
66(4):
470 - 475.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. F. Wong
Reply
Nephrol. Dial. Transplant.,
March 1, 2007;
22(3):
959 - 959.
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Flossmann, P. Bacon, K. de Groot, D. Jayne, N. Rasmussen, P. Seo, K. Westman, and R. Luqmani
Development of comprehensive disease assessment in systemic vasculitis
Ann Rheum Dis,
March 1, 2007;
66(3):
283 - 292.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. F. Wong
Rituximab in refractory antineutrophil cytoplasmic antibody-associated vasculitis: what is the current evidence?
Nephrol. Dial. Transplant.,
January 1, 2007;
22(1):
32 - 36.
[Full Text]
[PDF]
|
|
|
|
|
|
|
O Flossmann, R B Jones, D R W Jayne, and R A Luqmani
Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis?
Ann Rheum Dis,
July 1, 2006;
65(7):
841 - 844.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. D. Morgan, L. Harper, J. Williams, and C. Savage
Anti-Neutrophil Cytoplasm-Associated Glomerulonephritis
J. Am. Soc. Nephrol.,
May 1, 2006;
17(5):
1224 - 1234.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. A. Keogh, F. C. Fervenza, and U. Specks
Rituximab in Refractory Wegener's Granulomatosis: Favorable or Not?
Am. J. Respir. Crit. Care Med.,
April 1, 2006;
173(7):
816 - 816.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. M. Aries, P. Lamprecht, and W. L. Gross
Rituximab in refractory Wegener's granulomatosis: favorable or not?
Am. J. Respir. Crit. Care Med.,
April 1, 2006;
173(7):
815a - 8816.
[Full Text]
[PDF]
|
|
|
Copyright © 2006 American Thoracic Society
|
|
|
